Vantis Vascular Secures $10 Million in Series B-1 Funding
Vantis Vascular, Inc., an innovative medical technology company focused on transforming vascular interventions, is excited to announce the successful closure of a $10 million Series B-1 preferred financing round. This funding follows their previous $30 million raise contributed by high-net-worth individuals and National Institute of Health grants.
Utilization of Funds for Commercialization
The newly acquired funds will primarily support the commencement of U.S. commercialization for their groundbreaking CrossFAST™ Integrated Microcatheter Advanced Delivery System. This system is pivotal for improving patient outcomes, particularly in complex, high-risk percutaneous coronary interventions (PCIs).
Transformative Vision Behind Vantis Vascular
"We are immensely proud to have the continued backing of a robust group of investors who share our passion for revolutionizing how complex interventional procedures are conducted," stated Jason Turner, Chief Executive Officer at Vantis Vascular. This financing represents a significant milestone that empowers Vantis to enhance product development, expand their team, and facilitate the U.S. launch of the CrossFAST Advanced Delivery System.
The CrossFAST System: A Game Changer
The CrossFAST Advanced Delivery System stands out as the first and only dual monorail microcatheter advanced delivery system designed specifically for complex coronary and peripheral interventions. Unlike traditional guide extension catheters, the CrossFAST system eliminates the risks of vessel trauma and damage to previously placed stents.
Innovative Technology Enhancing Intervention Safety
Equipped with the proprietary DuoPRO™ Interlocking Technology, this system offers a seamless transition and enhanced pushability, addressing common limitations found in existing devices. This innovation allows for more effective navigation during complicated high-risk procedures.
Future Plans for Market Release
Following the successful financing round, Vantis plans to initiate a limited market release of the CrossFAST System in the United States. Gary McCord, Chief Commercial Officer, expressed confidence in the product's capabilities, emphasizing its design to safely navigate challenging anatomical structures, facilitating the delivery of life-saving therapies.
A Vision for Improved Patient Care
The CrossFAST Integrated Microcatheter Advanced Delivery System is currently available in the United States as part of a limited market release, with full commercial availability expected in the near future. Vantis Vascular is dedicated to advancing the field of interventional cardiology and aims to continue improving patient outcomes worldwide.
About Vantis Vascular
Vantis Vascular, Inc. is committed to revolutionizing vascular interventions with innovative, performance-driven technologies. Founded by a team of visionary physicians, Vantis is focused on developing safe, effective treatments that prioritize patient care and outcomes. Their mission is to lead advancements in interventional cardiology and provide efficient solutions in the medical field.
Frequently Asked Questions
What is Vantis Vascular known for?
Vantis Vascular is known for its innovative medical technologies aimed at transforming vascular interventions and enhancing patient outcomes.
What is the purpose of the CrossFAST System?
The CrossFAST System is designed for complex coronary and peripheral interventions, providing enhanced safety and navigation capabilities during procedures.
How much funding did Vantis Vascular secure?
Vantis Vascular secured $10 million in their Series B-1 preferred financing round.
What technology does the CrossFAST System utilize?
The CrossFAST System utilizes DuoPRO™ Interlocking Technology to improve pushability and navigate complex anatomical structures effectively.
When is the full market release for CrossFAST planned?
Full market release of the CrossFAST System is planned for the near future after initial limited market availability.
